CGRP mAb Subcutaneous denied as non-formulary by Aetna?

Aetna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Subcutaneous CGRP Monoclonal Antibodies as Non-Formulary — and Why You Can Appeal

A non-formulary denial means that the specific subcutaneous CGRP monoclonal antibody your prescriber selected is not included on Aetna's current drug formulary, or is on the formulary at a tier that requires additional authorization. Aetna's formulary preferences among CGRP agents can vary by plan year and by the specific employer-sponsored or marketplace plan you hold — there is no single universal formulary. The denial does not mean the drug is unsafe or ineffective; it reflects a contract between Aetna and the drug's manufacturer.

Two appeal paths exist in parallel: (1) a formulary exception appeal arguing that a formulary-preferred CGRP agent is clinically inappropriate for you, and (2) a standard medical-necessity appeal demonstrating that the requested agent is necessary for your specific circumstances.

## Federal Appeal Framework

Non-formulary denials are subject to ACA Section 2719 external review and ERISA Section 503 full-and-fair review. File an internal formulary exception request — or a combined exception-and-appeal — within approximately 180 days of the denial. If Aetna upholds the denial internally, request independent external review within approximately four months. Expedited review is available when delay threatens your health.

## Concrete Appeal Steps

1. Identify from the denial letter which specific agent was denied and which tier or formulary restriction applies. 2. Check Aetna's current formulary (available on your member portal) to identify whether an alternative CGRP agent is on-formulary and at what tier. 3. If your prescriber has a clinical reason to prefer the non-formulary agent over any on-formulary alternative — different adverse-effect profile, documented failure of the preferred agent, or a clinical distinction supported by the prescribing label — document that reason in writing. 4. Submit a formulary exception request accompanied by the documentation below.

## Documentation to Gather

• Prescriber medical-necessity letter: explaining why the specific non-formulary agent is medically necessary and why formulary alternatives are clinically inappropriate for this patient
• Prior-treatment records: if a formulary-preferred CGRP agent was previously tried and failed, document the dates, the response, and the clinical reason for switching
• Diagnosis documentation: confirming migraine diagnosis, frequency, and functional severity
• FDA prescribing label comparison: your prescriber may wish to note any clinically relevant distinctions between agents in the label that support the choice

## Criteria-Mapping Structure

Aetna's formulary exception criteria are typically published in its pharmacy exception policy. Copy each criterion and map your chart evidence to it. Pay particular attention to the "clinical appropriateness of alternatives" criterion — this is where most non-formulary exceptions are won or lost. If every on-formulary alternative has been tried and failed, or is documented as inappropriate, the exception is well-supported.